Nektar gets $100 million milestone payment from AstraZeneca

1 September 2015

Nektar Therapeutics (Nasdaq: NKTR) says it has received a $100 million payment under a license agreement with Anglo-Swedish pharma major AstraZeneca (LSE: AZN). The cash payment under the Nektar-AstraZeneca agreement was triggered by the first commercial sale of Movantik (naloxegol) in the USA.

Movantik is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) drug for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. It was approved by the US Food and Drug Administration last September, and was de-scheduled by the US Drug Enforcement Administration earlier this year. Subsequently, AstraZeneca inked a deal with Japanese peer Daiichi Sankyo (TYO: 4568) for the co-commercialization of Movantik (naloxegol) in the USA.

Terms of the collaboration

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK